Next Capital Management’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Next Capital Management’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,458	Closed	-$27K	–	112
2019 Q3	$27K	Hold	1,458	–	–	0.02%	178
2019 Q2	$31K	Hold	1,458	–	–	0.02%	209
2019 Q1	$31K	Buy	1,458 +285	+24%	+$5.98K	0.03%	169
2018 Q4	$22K	Buy	+1,173	New	+$24.4K	0.02%	164

Other funds holding CNCR

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Next Capital Management's CNCR Position: Q4 2019 in Review

Next Capital Management sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q4 2019, closing a stake of 1,458 shares — an estimated $27K sold.

Next Capital Management first reported a position in CNCR in Q4 2018 and held it in 4 quarters. The position peaked at $31K in Q2 2019. 23 funds tracked by Wall St. Rank hold CNCR as of Q4 2019.

Next Capital Management reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q4 2019 after selling out during the quarter.
Next Capital Management sold 1,458 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q4 2019, an estimated $27K.
Next Capital Management first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2018 and held it in 4 quarters.
Next Capital Management's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $31K in Q2 2019.
23 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q4 2019.

Based on Next Capital Management's 13F filing for Q4 2019, filed 12 Feb 2020.